MAPLE GROVE, Minn., Sept. 30, 2026 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths. According to IQVIA, the Fluvoxamine Maleate Extended-Release market had U.S. sales of approximately $44.6 million*.
The Therapeutic Equivalence (TE) code for Upsher-Smith's Fluvoxamine Maleate Extended-Release product is AB, and the Reference Listed Drug (RLD) is Luvox CR.
Product Information
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
Please see additional Important Safety Information, including Boxed Warning, and full Prescribing Information for Fluvoxamine Maleate Extended-Release Capsules here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch.
About Upsher-Smith
Upsher-Smith Laboratories, LLC, now a member of Bora Group, is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. We bring generics and brands to a wide array of customers, always backed by our attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.
About Bora
Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries. For more, please visit: https://www.bora-corp.com and https://www.boracdmo.com.
*August 2025 – July 2026
SOURCE Upsher-Smith Laboratories, LLC
Share this article